Two of Aurobindo’s biosimilars filings in Europe are likely delayed due to a lack of inspectors to examine its manufacturing facilities. However, another biosimilar filed in the UK might get an approval without the need for a Phase III efficacy trial.
An established generics player, Aurobindo has been building its biosimilars and specialty business in recent years,
Given that these hold the potential to push it past India’s number one company Sun Pharmaceutical Industries, analysts keenly watch biologics-related